版本:
中国

BRIEF-Denovo Biopharma obtains exclusive license to Liafensine from AMRI

April 24 Denovo Biopharma:

* Denovo Biopharma obtains exclusive license to Liafensine from AMRI

* Denovo Biopharma - under terms, Denovo Biopharma gains an exclusive license to all rights to develop, manufacture and commercialize Liafensine globally

* Denovo Biopharma - Liafensine was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events

* Denovo Biopharma - Liafensine program was not continued beyond phase 2 studies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐